Monthly Archives: October 2010
S*BIO’s JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission for the Treatment of Myelofibrosis Tools
Posted October 18, 2010
S*BIO’s JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)
SINGAPORE, Oct. 18 /PRNewswire/ — S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2… Continue reading
Tom Kramer/RACE of HIS LIFE
Ask any athlete and they will tell you getting in shape and staying there is a challenge. Preparing for the Ironman Triathlon in Hawaii is almost unimaginable. Tom Kramer knows all about challenges. He is training and running for the love of competition…and preparing for the Race of His Life.… Continue reading
Promising Results with Oral INCB018424 JAK Inhibitor
Oncology Times:
25 September 2010 – Volume 32 – Issue 18 – p 32
doi: 10.1097/01.COT.0000389882.98089.59
News
Myelofibrosis: Promising Results with Oral INCB018424 JAK Inhibitor
Free Access
An oral medication produced “significant and lasting relief” for patients with myelofibrosis in a study reported in the September 16th issue of the… Continue reading